Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum-based chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Efficacy was investigated in KEYNOTE-483 (ClinicalTrials.gov. Identifier: NCT02784171), a randomized, open-label trial in patients with unresectable advanced or metastatic MPM and no prior systemic